Clinical Trials Logo

Clinical Trial Summary

Doxycycline- and Furazolidone-containing Quadruple Regimen can be a successful rescue treatment for Helicobacter pylori Infection patients after Failure of several therapy. It is superior of tailored therapy as rescue treatment for helicobacter pylori Infection after failure of several therapy.


Clinical Trial Description

This study is a prospective, multiple centers, randomized trial. Patients who had failed in previous H. pylori eradication treatment that more than two times will be enrolled in Sir Run Run Shaw Hospital.

Pretreatment H. pylori status will be defined by a positive 13 C-urea breath test (13 C-UBT). Patients who had received bismuth compounds, acid inhibitor, or antibiotics during 4 weeks before 13 C-UBT are excluded. Other exclusion criteria included upper gastrointestinal surgery, malignancy, and evidence of blood dyscrasia.

After the patient is enrolled the patient will sign the informed consent and receive gastroscopy. More than four biopsy will be given including two in antrum and two in gastric body. One pair of biopsy sample will be sent for the pathology and the other pair is used for H.pylori culture and antibiotics sensitivity. After we get the result of antibiotics sensitivity the patient will be divided randomly into two groups, Regimen A, Regimen B.

The Regimen A includes esomeprazole (E) 20 mg, doxycycline (D) 100mg, furazolidone (F) 100 mg, and colloidal bismuth subcitrate (B) 100 mg . All drugs are taken twice a day for 14 days. The Regimen B includes two antibiotics based on antibiotic sensitivity of helicobacter pylori culture, colloidal bismuth subcitrate (B) 100 mg, esomeprazole (E) 20 mg. The esomeprazole and bismuth are taken half an hour before a meal and antibiotics after the meal.

All patients are asked to quit smoking and drinking and forbid eating foods rich in tyramine (e.g., chicken, cheese, pickles, lentils, beans) and seafood during and in 1 week after the treatment.

Patients will be followed up at the 1st day, 14th day, and 4 weeks after the treatment, respectively, and all side effects will be collected. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02894268
Study type Interventional
Source Sir Run Run Shaw Hospital
Contact Ning Dai, Chief
Phone +86138-6745-7664
Email 2267454962@qq.com
Status Recruiting
Phase Phase 4
Start date February 2016
Completion date December 2019

See also
  Status Clinical Trial Phase
Recruiting NCT02873247 - Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori N/A
Recruiting NCT02552641 - Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Phase 4
Active, not recruiting NCT02557932 - Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication Phase 3
Recruiting NCT02249546 - Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Phase 4
Completed NCT01933659 - Anti-H. Pylori Effect of Deep See Water Phase 3
Unknown status NCT01464060 - 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Phase 4
Completed NCT00841490 - Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults N/A
Recruiting NCT03134378 - 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication Phase 4
Not yet recruiting NCT02894892 - Intragastric pH and Bismuth Effect for H. Pylori Eradication Phase 4
Not yet recruiting NCT02961296 - Helicobacter Pylori Antibiotic Susceptibility Testing of Korea N/A
Completed NCT02528721 - Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection Phase 3
Completed NCT02596620 - Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication N/A
Completed NCT02359435 - Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection N/A
Active, not recruiting NCT00990405 - Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Phase 4
Completed NCT00736476 - Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults Phase 1
Completed NCT01730352 - Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Phase 2/Phase 3
Completed NCT00867867 - Ferrous Fumarate and Ferric Pyrophosphate as Food Fortificants in Developing Countries Phase 1
Completed NCT03193450 - Telephone-Based Re-education for Hp Eradication N/A
Recruiting NCT03317223 - A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients Phase 3
Not yet recruiting NCT03688828 - Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori N/A